Abstract
Capecitabine, an oral pro-drug of 5-fluorouracil, is part of the standard treatment of colorectal cancer (CRC). Severe adverse drug reactions that impair treatment safety remain a relevant concern. Hand-foot-syndrome (HFS) is the most frequently reported dose-limiting side effect of capecitabine. Genotyping of 4 variants of the DPYD gene is currently standard practice for capecitabine-related toxicity prediction. However, numerous studies have reported that single nucleotide polymorphisms (SNPs) in genes of capecitabine activation pathway (CES1, CES1P1, CES2, CDA, TYMP) may also contribute to individual variation in toxicity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
